Shanghai medical technology company Yikon Genomics raised ￥220 million in a series C round funding led by Jinhe Capital, and followed by Yuexiu Fund, Zhongyuan Jiupai Fund, Communication Bank Science and Innovation Fund. The investment will be used to develop and promote innovative patented products and services centering reproductive heredity, and women and children health.
Established in 2012, Yikon Genomics is committed to the development and application of single-cell separation and sequence to provide precise medical testing technology for sound pregnancy and personalized tumor diagnosis.
South Africa Today
Read more at VolaNews
